Back to Search
Start Over
HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis.
- Source :
-
Blood advances [Blood Adv] 2019 Sep 10; Vol. 3 (17), pp. 2581-2585. - Publication Year :
- 2019
-
Abstract
- HLA haploidentical hematopoietic cell transplantation (haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) is an alternative strategy when a matched sibling donor (MSD) is not available. We performed a systematic review and meta-analysis to compare the outcomes of MSD vs haplo-HCT. Eleven studies (1410 haplo-HCT and 6396 MSD recipients) were meta-analyzed. All studies were retrospective and high quality, and 9 were multicenter. Haplo-HCT was associated with ~50% lower risk of chronic graft-versus-host disease (GVHD) (hazard ratio [HR], 0.55; 95% confidence interval [CI], 0.41-0.74), but higher risk of nonrelapse mortality (HR, 1.36; 95% CI, 1.12-1.66). Relapse, survival, acute GVHD, and GVHD-free relapse-free survival were not significantly different between the groups. Deciphering the relative contribution of PT-Cy and HLA disparity to the observed outcome differences between the groups requires further research.<br /> (© 2019 by The American Society of Hematology.)
- Subjects :
- Cyclophosphamide therapeutic use
HLA Antigens immunology
Hematopoietic Stem Cell Transplantation adverse effects
Hematopoietic Stem Cell Transplantation standards
Humans
Retrospective Studies
Siblings
Transplantation, Haploidentical adverse effects
Transplantation, Haploidentical standards
Hematopoietic Stem Cell Transplantation methods
Histocompatibility immunology
Tissue Donors
Transplantation, Haploidentical methods
Subjects
Details
- Language :
- English
- ISSN :
- 2473-9537
- Volume :
- 3
- Issue :
- 17
- Database :
- MEDLINE
- Journal :
- Blood advances
- Publication Type :
- Academic Journal
- Accession number :
- 31484635
- Full Text :
- https://doi.org/10.1182/bloodadvances.2019000614